Comparison of transcriptional activation by corticosteroids of human MR (Ile-180) and haplotype (Val-180).
Katsu, Yoshinao, Zhang, Jiawen, Ao, Ya et al. · Biochemical and biophysical research communications · 2026 · DOI
Quick Summary
This study examined how a common genetic variation in the mineralocorticoid receptor (MR)—a protein that helps the body respond to stress hormones—works differently than the standard version. Researchers tested whether existing medications (spironolactone and progesterone) could block this variant receptor in brain cells. The findings suggest these medications might help regulate overactive stress responses that could contribute to chronic fatigue symptoms.
Why It Matters
Since ME/CFS involves dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and abnormal stress hormone responses, understanding how genetic variants affect stress hormone receptors in the brain could illuminate disease mechanisms. Identifying effective antagonists for this MR variant may offer a therapeutic avenue for managing hyperactivity and stress-related symptoms in ME/CFS patients.
Observed Findings
MR rs5522 showed higher EC50 (lower cortisol affinity) and reduced fold-activation for cortisol compared to wild-type MR in TAT3-containing cells.
MR rs5522 demonstrated slightly lower EC50 and higher fold-activation for aldosterone and corticosterone in TAT3-containing cells.
Spironolactone and progesterone were equally effective antagonists of both MR variants across both promoter contexts.
With the MMTV promoter, MR rs5522 and wild-type MR showed minimal functional differences.
Promot-context significantly influenced the functional behavior of the MR rs5522 variant.
Inferred Conclusions
The MR rs5522 variant exhibits promoter-dependent functional differences, particularly in cortisol sensitivity, suggesting variant-specific signaling contexts in different brain regions or cell types.
Existing MR antagonists (spironolactone and progesterone) retain similar blocking capacity against the MR rs5522 variant, making them potential candidates for modulating this variant's activity in the brain.
The differential response to different corticosteroids by the MR rs5522 variant may have implications for stress-related disorders involving altered HPA axis function.
Remaining Questions
Does the MR rs5522 variant actually occur at higher frequency in ME/CFS patients compared to healthy controls, and does it correlate with disease severity or specific symptoms?
What This Study Does Not Prove
This study does not establish that the MR rs5522 variant actually causes ME/CFS or contributes to disease in patients—it is an in vitro mechanistic study in cell culture, not human clinical research. The authors' suggestion about treating 'hyperactivity that contributes to chronic fatigue syndrome' is speculative and not directly supported by patient data in this study. Demonstrating that antagonists can block the receptor in cells does not prove they would be effective, safe, or beneficial in living ME/CFS patients.
Would spironolactone or progesterone antagonists have therapeutic effects in ME/CFS patients carrying this variant, and what would be appropriate dosing and safety profiles?
What is the functional significance of promoter-dependent effects in vivo—which brain regions express which promoter context, and how does this affect stress response in living organisms?
Do other genetic variations in the MR or related stress-response genes interact with rs5522 to influence ME/CFS susceptibility or HPA axis dysfunction?